Click here for slides on this topic


Sitagliptin

An oral antihyperglycemic agent of the dipeptidyl peptidase-4 (DPP-4) inhibitor class.
The following content matched the glossary term: Sitagliptin

No Heart Failure Risk With DPP-4 Inhibitor, Sitagliptin, in TECOS Subanalysis

Top

Data from a subanalysis of TECOS at ESC Congress 2015 confirms that the DPP-4 inhibitor, sitagliptin, does not cause heart failure in patients with type 2 diabetes. Includes expert commentary.

NDEI.org Expert Commentary Silvio Inzucchi MD on TECOS Subanalysis No Heart Failure Risk With Sitagliptin in High-Risk Type 2 Diabetes

Top

Silvio Inzucchi, MD, provides expert commentary on data from a subanalysis of TECOS, which confirmed that the DPP-4 inhibitor, sitagliptin, does not cause heart failure in patients with type 2 diabetes; from ESC Congress 2015.

NDEI.org Expert Commentary Vivian Fonseca, MD, on Results of TECOS, the Cardiovascular Safety Study of the DPP-4 Inhibitor Sitagliptin

Top

Vivian Fonseca provides expert insights on results of the TECOS cardiovascular safety study of the DPP-4 inhibitor, sitagliptin

ADA 2015: The 75th Scientific Sessions of the American Diabetes Association

Top

Coverage of data from ADA 2015, June 5-9, 2015 in Boston, Massachusetts

CompanionSetType2DiabetesMedications

Top

Patient education companion set featuring handouts on DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and medications used to treat type 2 diabetes (English and Spanish)

Medications Used To Treat Type 2 Diabetes

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose.

HARMONY 3: 104-week trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride

Top

Ahrén B, Johnson SL, Stewart M, et al; for the HARMONY 3 Study Group. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care. 2014;37(8):2141-2148.

Medicamentos para el tratamiento de la diabetes tipo 2

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose—in Spanish.

NDEI.org Expert Commentary on Type 2 Diabetes Treatment Trends from Vivian Fonseca, MD

Top

NDEI Education Council Member Vivian A. Fonseca, MD, comments on a study exploring type 2 diabetes treatment trends in the U.S.: “Clinicians could use these data to determine whether their own prescribing has changed in line with national trends”

Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012

Top

Exclusive! Expert commentary from Vivian A. Fonseca, MD, on this study. Turner LW, Nartey D, Stafford RS, Singh S, Alexander GC. Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012. Diabetes Care. 2014;37:985-992.

1 2 3 4 5 6 7 8 Next 

Slide Library Results

Search Results for: Sitagliptin Slides Found: 82
Single Doses of Sitagliptin Increase Incretin Levels Over 24 Hours
Patients Achieving ADA A1C Goal on 18-Wk Sitagliptin Monotherapy
18-Wk Sitagliptin Monotherapy Improves Glycemic Control
18-Wk Sitagliptin Monotherapy Improves b-Cell Function
24-Week Sitagliptin Monotherapy Improves Glycemic Control in Patients With Type 2 Diabetes
Sitagliptin Enhances Glycemic Control, beta-Cell Function in Patients With Type 2 Diabetes Not Controlled With Metformin
Sitagliptin Improves Glycemic Control in Patients With Type 2 Diabetes Not Controlled With Pioglitazone
Effects of Sitagliptin vs Glipizide on Body Weight in Type 2 Diabetes
Change in A1C for Sitagliptin vs Glipizide in Patients Not Controlled With Metformin
Sitagliptin + Metformin Improves 24-Hour Glycemic Control
Sitagliptin Improves A1C in Patients With Type 2 Diabetes Not Controlled With Metformin
Sitagliptin Reduces FPG in Patients With Type 2 Diabetes Not Controlled With Metformin
Effect of Sitagliptin on 2-Hour Post-Meal Plasma Glucose in Patients With Type 2 Diabetes Not Controlled With Metformin
Sitagliptin Monotherapy Reduces FPG in Patients With Type 2 Diabetes
Effect of Sitagliptin Monotherapy on A1C in Patients With Type 2 Diabetes
Effect of Sitagliptin Monotherapy on 2-Hour Postprandial Glucose in Patients With Type 2 Diabetes
Sitagliptin Improves A1C in Patients With Type 2 Diabetes Not Controlled With Pioglitazone
Sitagliptin Reduces FPG in Patients With Type 2 Diabetes Not Controlled With Pioglitazone
Changes in A1C Subgroups for Sitagliptin vs Glipizide in Patients Not Controlled With Metformin
Effects of Sitagliptin vs Glipizide on FPG in Patients With Type 2 Diabetes Not Controlled With Metformin
Effect of Sitagliptin + Metformin on A1C in Patients With Type 2 Diabetes
Effect of Sitagliptin + Metformin on FPG in Patients with Type 2 Diabetes
Effect of Sitagliptin + Metformin on B-Cell Function at 24 Weeks
Frequent Adverse Events in Diabetic Patients Treated With GLP-1 Analogues
Frequent Adverse Events in Diabetic Patients Treated With DPP-4 Inhibitors
Change in A1C for DPP-4 Inhibitors vs Control in Diabetic Adults
Change in A1C for DPP-4 Inhibitors vs Control in Diabetic Adults (cont)
Suitability of DPP-4 Inhibitors for Elderly Patients With Type 2 Diabetes
Effect of Sitagliptin Added to Glimepiride and/or Metformin in Patients With Type 2 Diabetes
Glycemic Control With Addition of Sitagliptin to Glimepiride and/or Metformin
Effect of Sitagliptin vs Rosiglitazone When Added to Metformin Monotherapy
Liraglutide Vs Sigagliptin for Type 2 Diabetes Inadequately Controlled With Metformin: Design
Liraglutide Vs Sitagliptin for Type 2 Diabetes Inadequately Controlled With Metformin: A1C
Liraglutide Vs Sitagliptin for Type 2 Diabetes: 1-Year Results Design
Liraglutide Vs Sitagliptin for Type 2 Diabetes: 1-Year Results A1C Reduction
Liraglutide Vs Sitagliptin for Type 2 Diabetes: 1-Year Results
Liraglutide Vs Sitagliptin for Type 2 Diabetes: 1-Year Results
DURATION-4: Design
DURATION-4: Mean Change in A1C from Baseline to Week 26
DURATION-4: Additional Outcomes
DURATION-4: Most Common Adverse Events
EASIE Trial: Design
EASIE Trial: Study and Enrollment Profile
EASIE Trial: Efficacy Population Primary Outcome at Week 24—Change in A1C from Baseline
EASIE Trial: Efficacy Population A1C <7.0% and <6.5% Week 24
EASIE Trial: Safety Population Hypoglycemia and Adverse Events
Switching from Sitagliptin to Liraglutide After 52 Weeks of Treatment: Design
Switching from Sitagliptin to Liraglutide After 52 Weeks of Treatment: 26-Week Extension Results for A1C Reduction
Liraglutide Treatment for 78 Weeks: Reductions in A1C from Baseline
CANTATA-D2: Design
CANTATA-D2: Canagliflozin Noninferior to Sitagliptin for A1C Lowering at 52 Weeks
CANTATA-D2: Significantly Greater FPG Reduction with Canagliflozin Vs Sitagliptin at 52 Weeks
CANTATA-D2: Significantly Greater Weight Reduction with Canagliflozin Vs Sitagliptin at 52 Weeks
CANTATA-D2: Significant Reductions in Systolic BP with Canagliflozin Vs Sitagliptin at 52 Weeks
CANTATA-D2: Effect of Canagliflozin Vs Sitagliptin on Lipid Values at 52 Weeks
CANTATA-D2: Adverse Events at 52 Weeks
DPP-4 Inhibitors: Dosage Adjustment by Degree of Renal Impairment
Incretin Therapies Vs Sulfonylureas Pancreatitis Type 2 Diabetes | NDEI
HARMONY 3 Albiglutide A1C Type 2 Diabetes | NDEI
HARMONY 3 Albiglutide FPG Type 2 Diabetes | NDEI
HARMONY 3 Albiglutide DPP-4 Inhibitor Weight Loss Type 2 Diabetes | NDEI
HARMONY 3 Albiglutide DPP-4 Inhibitor Type 2 Diabetes | NDEI
HARMONY 3 Albiglutide Type 2 Diabetes Metformin | NDEI
GLP-1 Receptor Agonists A1C Type 2 Diabetes | NDEI
HARMONY 3 DPP-4 Inhibitors Safety Pancreatitis | NDEI
Risk of Acute Pancreatitis Rare in Incretin-Treated Type 2 Diabetes | NDEI
No Increased Acute Pancreatitis Risk With Incretins Type 2 Diabetes | NDEI
Canagliflozin & Sitagliptin A1C Type 2 Diabetes ENDO2015 PPT | NDEI
TECOS Sitagliptin Cardiovascular Safety High-Risk Type 2 Diabetes DPP-4 | NDEI
TECOS Cardiovascular Outcomes Sitagliptin DPP-4 | NDEI
TECOS Heart Failure Sitaliptin DPP-4 CV Safety | NDEI
TECOS Sitagliptin DPP-4 Inhibitor Pancreatitis Hypoglycemia | NDEI
TECOS Sitagliptin A1C Efficacy DPP-4 Inhibitor CV Safety | NDEI
Sitagliptin Not Associated With Heart Failure in TECOS Type 2 Diabetes | NDEI
Type 2 Diabetes Is Associated With Cardiovascular Outcomes | NDEI
Connection Between Type 2 Diabetes and Heart Failure PPT | NDEI
Relationship Between DPP-4 Inhibitors & Heart Failure Diabetes | NDEI
Key Points from TECOS Subanalysis Sitagliptin DPP-4 | NDEI PPT
No Heart Failure Hospitalization Risk With Sitagliptin in TECOS | NDEI
No Increased Risk of HF Hospitalization, CV Death With Sitagliptin TECOS | NDEI
Effect of DPP-4 Inhibitors Vs Placebo on Heart Failure in Diabetes | NDEI
TECOS No HF Hospitalization Risk With Sitagliptin Treatment Diabetes | NDEI